Categories AlphaGraphs, Earnings, Technology

Earnings: Highlights of BlackBerry’s (BB) Q2 2023 results

Smartphone company BlackBerry Limited (NYSE: BB) has reported total revenues of $168 million for the second quarter of 2023, compared to $175 million in the same period last year.

BlackBerry Q2 2022 earnings infographic

During the three-month period, the tech firm incurred a net loss of $54 million or $0.10 per share, compared to a loss of $144 million or $0.25 per share in the prior-year quarter. Second-quarter adjusted loss, on a per-share basis, was $0.05 per share, compared to a loss of $0.06 per share in the same period of last year.

Check this space to read management/analysts’ comments on BlackBerry’s Q2 2023 earnings

“Our IoT business continues to gain market share, and design-phase revenue remained at near-record levels. A major design win in the quarter was with Volkswagen, who chose QNX for their new VW.OS, to be deployed across all Volkswagen group brands. IVY remains firmly on track, with the latest product release in August, proof of concept trials progressing well, and the IVY fund continuing to invest in exciting ecosystem partners,” said John Chen, CEO of BlackBerry.


Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock


Most Popular

Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results

DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line

Macy’s (M): A few points to consider if you have an eye on this retailer

Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit

Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent

Add Comment
Viewing Highlight